Top Buy Now Summary References
Home
>
Section
>
Chapter

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) : a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Mallory, R.M.; Formica, N.; Pfeiffer, S.; Wilkinson, B.; Marcheschi, A.; Albert, G.; McFall, H.; Robinson, M.; Plested, J.S.; Zhu, M.; Cloney-Clark, S.; Zhou, B.; Chau, G.; Robertson, A.; Maciejewski, S.; Hammond, H.L.; Baracco, L.; Logue, J.; Frieman, M.B.; Smith, G.; Patel, N.; Glenn, G.M.; Adams, M.; Arya, M.; Athan, E.; Berger, I.; Bradley, P.; Briskin, T.; Glover Ii, R.; Griffin, P.; Kim, J.; Kitchener, S.; Klein, T.; Leah, A.; Leelasena, I.; Lemech, C.; Lickliter, J.; Manning, M.B.; Napier

LANCET. Infectious Diseases 22(11): 1565-1576

2022

ISSN/ISBN: 1474-4457
PMID: 35963274
Accession: 080190401

Full-Text Article emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Summary
Emerging SARS-CoV-2 variants and evidence of waning vaccine efficacy present substantial obstacles towards controlling the COVID-19 pandemic. Booster doses of SARS-CoV-2 vaccines might address these concerns by amplifying and broadening the immune responses seen with initial vaccination regimens. We aimed to assess the immunogenicity and safety of a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373). This secondary analysis of a phase 2, randomised study assessed a single booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M adjuvant (NVX-CoV2373) in healthy adults aged 18-84 years, recruited from 17 clinical centres in the USA and Australia. Eligible participants had a BMI of 17-35 kg/m2 and, for women, were heterosexually inactive or using contraception. Participants who had a history of SARS-CoV or SARS-CoV-2, confirmed diagnosis of COVID-19, serious chronic medical conditions, or were pregnant or breastfeeding were excluded. Approximately 6 months following their primary two-dose vaccination series (administered day 0 and day 21), participants who received placebo for their primary vaccination series received a placebo booster (group A) and participants who received NVX-CoV2373 for their primary vaccination series (group B) were randomly assigned (1:1) again, via centralised interactive response technology system, to receive either placebo (group B1) or a single booster dose of NVX-CoV2373 (5 μg SARS-CoV-2 rS with 50 μg Matrix-M adjuvant; group B2) via intramuscular injection; randomisation was stratified by age and study site. Vaccinations were administered by designated site personnel who were masked to treatment assignment, and participants and other site staff were also masked. Administration personnel also assessed the outcome. The primary endpoints are safety (unsolicited adverse events) and reactogenicity (solicited local and systemic) events and immunogenicity (serum IgG antibody concentrations for the SARS-CoV-2 rS protein antigen) assessed 14 days after the primary vaccination series (day 35) and 28 days following booster (day 217). Safety was analysed in all participants in groups A, B1, and B2, according to the treatment received; immunogenicity was analysed in the per-protocol population (ie, participants in groups A, B1, and B2) who received all assigned doses and who did not test SARS-CoV-2-positive or received an authorised vaccine, analysed according to treatment assignment). This trial is registered with ClinicalTrials.gov, NCT04368988. 1610 participants were screened from Aug 24, 2020, to Sept 25, 2020. 1282 participants were enrolled, of whom 173 were assigned again to placebo (group A), 106 were re-randomised to NVX-CoV2373-placebo (group B1), and 104 were re-randomised to NVX-CoV2373-NVX-CoV2373 (group B2); after accounting for exclusions and incorrect administration, 172 participants in group A, 102 in group B1, and 105 in group B2 were analysed for safety. Following the active booster, the proportion of participants with available data reporting local (80 [82%] of 97 participants had any adverse event; 13 [13%] had a grade ≥3 event) and systemic (75 [77%] of 98 participants had any adverse event; 15 [15%] had a grade ≥3 event) reactions was higher than after primary vaccination (175 [70%] of 250 participants had any local adverse event, 13 [5%] had a grade ≥3 event; 132 [53%] of 250 had any systemic adverse event, 14 [6%] had a grade ≥3 event). Local and systemic events were transient in nature (median duration 1·0-2·5 days). In the per-protocol immunogenicity population at day 217 (167 participants in group A, 101 participants in group B1, 101 participants in group B2), IgG geometric mean titres (GMT) had increased by 4·7-fold and MN50 GMT by 4·1-fold for the ancestral SARS-CoV-2 strain compared with the day 35 titres. Administration of a booster dose of NVX-CoV2373 resulted in an incremental increase in reactogenicity. For both the prototype strain and all variants evaluated, immune responses following the booster were similar to or higher than those associated with high levels of efficacy in phase 3 studies of the vaccine. These data support the use of NVX-CoV2373 in booster programmes. Novavax and the Coalition for Epidemic Preparedness Innovations.

References

Tabarsi, P.; Anjidani, N.; Shahpari, R.; Roshanzamir, K.; Fallah, N.; Andre, G.; Petrovsky, N.; Barati, S. 2022: Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: a randomized placebo-controlled trial Immunology 167(3): 340-353
Bennett, C.; Woo, W.; Bloch, M.; Cheung, K.; Griffin, P.; Mohan, R.; Deshmukh, S.; Arya, M.; Cumming, O.; Neville, A.M.; McCallum Pardey, T.G.; Plested, J.S.; Cloney-Clark, S.; Zhu, M.; Kalkeri, R.; Patel, N.; Marcheschi, A.; Swan, J.; Smith, G.; Cho, I.; Glenn, G.M.; Walker, R.; Mallory, R.M.; Anderson, A.; Ang, M.; Barnes, T.; Bassin, M.; Bessey, K.; Bowler, S.; Bull, S.; Burr, L.; Burton, R.; Byrne, M.; Carroll, R.; Chee, N.; Choy, A.; Clark, M.; Dalebout, M.; De Wet, P.; Deshmukh, K.; Diez Alvarez, S.; Douglas, D.; Engelander, J.; Evangelista, C.; Game, S.; Glass, N.; Gunner, E.; Han, J.; Harrison, M.; Hing Kiang, J.D.; Hlaing, T.; Joshi, D.; Joyce, S.; Kaluhin, K.; Kavic, M.; Kononov, J.; Lee, G.; Lee, W.-I.; Leelasena, I.; Leong, E.;, 2024: Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial LANCET. Infectious Diseases 24(6): 581-593
Hernández-Bernal, F.; Ricardo-Cobas, M.C.; Martín-Bauta, Y.; Navarro-Rodríguez, Z.; Piñera-Martínez, M.; Quintana-Guerra, J.; Urrutia-Pérez, K.; Urrutia-Pérez, K.; Chávez-Chong, C.O.; Azor-Hernández, J.L.; Rodríguez-Reinoso, J.é L.; Lobaina-Lambert, L.; Colina-Ávila, E.; Bizet-Almeida, J.; Rodríguez-Nuviola, J.; Del Valle-Piñera, S.; Ramírez-Domínguez, M.; Tablada-Ferreiro, E.; Alonso-Valdés, M.; Lemos-Pérez, G.; Guillén-Nieto, G.E.; Palenzuela-Díaz, A.; Noa-Romero, E.; Limonta-Fernández, M.; Fernández-Ávila, J.M.; Ali-Mros, N.A.; Del Toro-Lahera, L.; Remedios-Reyes, R.; Ayala-Ávila, M.; Muzio-González, V.L. 2022: Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study) Eclinicalmedicine 46: 101383
Pitisuttithum, P.; Luvira, V.; Lawpoolsri, S.; Muangnoicharoen, S.; Kamolratanakul, S.; Sivakorn, C.; Narakorn, P.; Surichan, S.; Prangpratanporn, S.; Puksuriwong, S.; Lamola, S.; Mercer, L.D.; Raghunandan, R.; Sun, W.; Liu, Y.; Carreño, J.M.; Scharf, R.; Phumratanaprapin, W.; Amanat, F.; Gagnon, L.; Hsieh, C.-L.; Kaweepornpoj, R.; Khan, S.; Lal, M.; McCroskery, S.; McLellan, J.; Mena, I.; Meseck, M.; Phonrat, B.; Sabmee, Y.; Singchareon, R.; Slamanig, S.; Suthepakul, N.; Tcheou, J.; Thantamnu, N.; Theerasurakarn, S.; Tran, S.; Vilasmongkolchai, T.; White, J.A.; Bhardwaj, N.; Garcia-Sastre, A.; Palese, P.; Krammer, F.; Poopipatpol, K.; Wirachwong, P.; Hjorth, R.; Innis, B.L. 2022: Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial Eclinicalmedicine 45: 101323
Pitisuttithum, P.; Luvira, V.; Lawpoolsri, S.; Muangnoicharoen, S.; Kamolratanakul, S.; Sivakorn, C.; Narakorn, P.; Surichan, S.; Prangpratanporn, S.; Puksuriwong, S.; Lamola, S.; Mercer, L.D.; Raghunandan, R.; Sun, W.; Liu, Y.; Carreño, J.M.; Scharf, R.; Phumratanaprapin, W.; Amanat, F.; Gagnon, L.; Hsieh, C.-L.; Kaweepornpoj, R.; Khan, S.; Lal, M.; McCroskery, S.; McLellan, J.; Mena, I.; Meseck, M.; Phonrat, B.; Sabmee, Y.; Singchareon, R.; Slamanig, S.; Suthepakul, N.; Tcheou, J.; Thantamnu, N.; Theerasurakarn, S.; Tran, S.; Vilasmongkolchai, T.; White, J.A.; Garcia-Sastre, A.; Palese, P.; Krammer, F.; Poopipatpol, K.; Wirachwong, P.; Hjorth, R.; Innis, B.L. 2021: Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial Medrxiv: the Preprint Server for Health Sciences 2021
Nguyen, T.P.; Do, Q.; Phan, L.T.; Dinh, D.V.; Khong, H.; Hoang, L.V.; Nguyen, T.V.; Pham, H.N.; Chu, M.V.; Nguyen, T.T.; Pham, Q.D.; Le, T.M.; Trang, T.N.T.; Dinh, T.T.; Vo, T.V.; Vu, T.T.; Nguyen, Q.B.P.; Phan, V.T.; Nguyen, L.V.; Nguyen, G.T.; Tran, P.M.; Nghiem, T.D.; Tran, T.V.; Nguyen, T.G.; Tran, T.Q.; Nguyen, L.T.; Do, A.T.; Nguyen, D.D.; Ho, S.A.; Nguyen, V.T.; Pham, D.T.; Tran, H.B.; Vu, S.T.; Hoang, S.X.; Do, T.M.; Nguyen, X.T.; Le, G.Q.; Tran, T.; Cao, T.M.; Dao, H.M.; Nguyen, T.T.T.; Doan, U.Y.; Le, V.T.T.; Tran, L.P.; Nguyen, N.M.; Nguyen, N.T.; Pham, H.T.T.; Nguyen, Q.H.; Nguyen, H.T.; Nguyen, H.L.K.; Tran, V.T.; Tran, M.T.N.; Nguyen, T.T.T.; Ha, P.T.; Huynh, H.T.; Nguyen, K.D.; Thuan, U.T.; Doan, C.C.; Do, S.M. 2022: Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial Lancet Regional Health. Western Pacific 24: 100474
Goepfert, P.A.; Fu, B.; Chabanon, A.-L.; Bonaparte, M.I.; Davis, M.G.; Essink, B.J.; Frank, I.; Haney, O.; Janosczyk, H.; Keefer, M.C.; Koutsoukos, M.; Kimmel, M.A.; Masotti, R.; Savarino, S.J.; Schuerman, L.; Schwartz, H.; Sher, L.D.; Smith, J.; Tavares-Da-Silva, F.; Gurunathan, S.; DiazGranados, C.A.; de Bruyn, G. 2021: Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study LANCET. Infectious Diseases 21(9): 1257-1270
Hernández-Bernal, F.; Ricardo-Cobas, M.C.; Martín-Bauta, Y.; Rodríguez-Martínez, E.; Urrutia-Pérez, K.; Urrutia-Pérez, K.; Quintana-Guerra, J.; Navarro-Rodríguez, Z.; Piñera-Martínez, M.; Rodríguez-Reinoso, J.é L.; Chávez-Chong, C.O.; Baladrón-Castrillo, I.; Melo-Suárez, G.; Batista-Izquierdo, A.; Pupo-Micó, A.; Mora-Betancourt, R.; Bizet-Almeida, J.; Martínez-Rodríguez, M.C.; Lobaina-Lambert, L.; Velázquez-Pérez, V.M.; Soler-Díaz, J.; Laurencio-Vallina, S.; Meriño-Hechavarría, T.; Carmenaty-Campos, N.; Rodríguez-Montero, E.; Limonta-Fernández, M.; Alonso-Valdés, M.; Hernández-Rodríguez, R.; Pimentel-Vázquez, E.; Catasús-Álvarez, K.M.; Cabrera-Núñez, M.V.; Ayala-Ávila, M.; Muzio-González, V.L.; Hernández-B 2023: A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study) Lancet Regional Health. Americas 21: 100497
Chappell, K.J.; Mordant, F.L.; Li, Z.; Wijesundara, D.K.; Ellenberg, P.; Lackenby, J.A.; Cheung, S.T.M.; Modhiran, N.; Avumegah, M.S.; Henderson, C.L.; Hoger, K.; Griffin, P.; Bennet, J.; Hensen, L.; Zhang, W.; Nguyen, T.H.O.; Marrero-Hernandez, S.; Selva, K.J.; Chung, A.W.; Tran, M.H.; Tapley, P.; Barnes, J.; Reading, P.C.; Nicholson, S.; Corby, S.; Holgate, T.; Wines, B.D.; Hogarth, P.M.; Kedzierska, K.; Purcell, D.F.J.; Ranasinghe, C.; Subbarao, K.; Watterson, D.; Young, P.R.; Munro, T.P. 2021: Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial LANCET. Infectious Diseases 21(10): 1383-1394
Alves, K.; Kotloff, K.L.; McClelland, R.S.; Kouassi, A.; Plested, J.S.; Kalkeri, R.; Zhu, M.; Cloney-Clark, S.; Cai, Z.; Smith, K.A. 2025: Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study The Lancet Infectious Diseases 25(5): 585-594
Thiem, V.D.; Anh, D.D.; Ha, V.H.; Van Thom, N.; Thang, T.C.; Mateus, J.; Carreño, J.M.; Raghunandan, R.; Huong, N.M.; Mercer, L.D.; Flores, J.; Escarrega, E.A.; Raskin, A.; Thai, D.H.; Van Be, L.; Sette, A.; Innis, B.L.; Krammer, F.; Weiskopf, D. 2025: Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: a randomised, comparator-controlled, phase 2 trial Vaccine 44: 126542
Hannawi, S.; Saf Eldin, L.; Abuquta, A.; Alamadi, A.; Mahmoud, S.A.; Li, J.; Chen, Y.; Xie, L. 2023: Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial Journal of Infection 86(2): 154-225
Hannawi, S.; Saifeldin, L.; Abuquta, A.; Alamadi, A.; Mahmoud, S.A.; Hassan, A.; Liu, D.; Yan, L.; Xie, L. 2023: Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial Ebiomedicine 87: 104386
Robbins, J.A.; Tait, D.; Huang, Q.; Dubey, S.; Crumley, T.; Cote, J.; Luk, J.; Sachs, J.R.; Rutkowski, K.; Park, H.; Schwab, R.; Howitt, W.J.; Rondon, J.C.; Hernandez-Illas, M.; O'Reilly, T.; Smith, W.; Simon, J.; Hardalo, C.; Zhao, X.; Wnek, R.; Cope, A.; Lai, E.; Annunziato, P.; Guris, D.; Stoch, S.A. 2022: Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial Ebiomedicine 82: 104138
Thiem, V.D.; Anh, PTV; Men, V.; C; Hung, D.T.; Pollard, A.J.; Kamitani, A.; Tada, Y.; Fukuyama, H.; Iwasaki, Y.; Ariyasu, M.; Sonoyama, T. 2024: A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial Vaccine 42
Wagner, L.; Obersriebnig, M.; Hochreiter, R.; Kadlecek, V.; Larcher-Senn, J.; Hegele, L.; Maguire, J.D.; Murphy, T.; Derhaschnig, U.; Bézay, N.; Jaramillo, J.C.; Eder-Lingelbach, S.; Messier, M. 2025: Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial LANCET. Infectious Diseases 2025
Ghadge, S.K.; Schneider, M.; Dubischar, K.; Wagner, L.; Kadlecek, V.; Obersriebnig, M.; Hochreiter, R.; Klingler, A.; Larcher-Senn, J.; Derhaschnig, U.; Bender, W.; Eder-Lingelbach, S.; Bézay, N. 2024: Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial LANCET. Infectious Diseases 24(11): 1275-1286
Tabarsi, P.; Anjidani, N.; Shahpari, R.; Mardani, M.; Sabzvari, A.; Yazdani, B.; Roshanzamir, K.; Bayatani, B.; Taheri, A.; Petrovsky, N.; Li, L.; Barati, S. 2022: Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations Clinical Microbiology and Infection: the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 28(9): 1263-1271
Formica, N.; Mallory, R.; Albert, G.; Robinson, M.; Plested, J.S.; Cho, I.; Robertson, A.; Dubovsky, F.; Glenn, G.M. 2021: Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial Plos Medicine 18(10): E1003769
Lioznov, D.; Amosova, I.; Sheetikov, S.A.; Zornikova, K.V.; Serdyuk, Y.; Efimov, G.A.; Tsyferov, M.; Khmelevskii, M.; Afanasiev, A.; Khomyakova, N.; Zubkov, D.; Tikhonov, A.; Zhu, T.; Barreto, L.; Dzutseva, V. 2023: Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia PLOS one 18(3): E0278878